PT  - JOURNAL ARTICLE
AU  - Lorenzo R Carnio
AU  - Mary E Johnson Shaw
AU  - Jack Schnur
AU  - Damian Casadesus
TI  - Concurrent terbinafine-induced acute generalised exanthematous pustulosis and hepatitis
AID  - 10.1136/bcr-2020-238930
DP  - 2021 Jan 01
TA  - BMJ Case Reports
PG  - e238930
VI  - 14
IP  - 1
4099  - http://casereports.bmj.com/content/14/1/e238930.short
4100  - http://casereports.bmj.com/content/14/1/e238930.full
SO  - BMJ Case Reports2021 Jan 01; 14
AB  - Terbinafine is a commonly used antifungal medication. Its side effects, while widely known, are rarely described and can be missed by the medical community. We present a 55-year-old woman who visited her primary care physician with onychomycosis. She started treatment with terbinafine, and 1 week later developed a rash in the left flank that extended to the chest, back, and upper part of lower extremities. Laboratory results showed elevated liver enzymes. A treatment with steroids did not improve the rash and she was admitted to our institution. She was started with intravenous dexamethasone, topical hydrocortisone and triamcinolone. Seven days later the liver enzymes normalised, and the rash resolved on the chest and back. Our patient had concurrent acute generalised exanthematous pustulosis and hepatitis that together has been very rarely associated with terbinafine.